Beta-Blockers in Heart Failure Patients with Preserved Systolic Function

Findings from a SENIORS substudy suggest that the benefits of beta blockade extend to patients without LVSD.

Despite several trials, effective evidence-based therapies for patients with heart failure and preserved LV systolic function remain frustratingly elusive. Investigators for the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure (SENIORS) assessed the efficacy of the vasodilating beta-1 receptor blocker nebivolol in adults aged ≥70 with heart failure and a broad range of LV systolic function. In the complete SENIORS cohort, nebivolol treatment resulted in a marginally statistically significant reduction in the risk for death or cardiovascular hospitalization (hazard ratio, 0.86). In this prespecified substudy, the authors compared the results in patients with LV systolic dysfunction (L…

Reviewing Author

Frederick A. Masoudi, MD, MSPH

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)

Frederick A. Masoudi, MD, MSPH

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)

Beta-Blockers in Heart Failure Patients with Preserved Systolic Function

Topics

Reviewing Author